On Tuesday, Relay Therapeutics Inc (NASDAQ: RLAY) was -4.52% drop from the session before settling in for the closing price of $3.10. A 52-week range for RLAY has been $3.02 – $10.72.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 307.65%. When this article was written, the company’s average yearly earnings per share was at 6.14%. With a float of $127.70 million, this company’s outstanding shares have now reached $167.76 million.
Let’s determine the extent of company efficiency that accounts for 261 employees. In terms of profitability, gross margin is 72.39%, operating margin of -3854.04%, and the pretax margin is -3374.72%.
Relay Therapeutics Inc (RLAY) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Relay Therapeutics Inc stocks. The insider ownership of Relay Therapeutics Inc is 24.67%, while institutional ownership is 80.01%. The most recent insider transaction that took place on Feb 11 ’25, was worth 539,701. In this transaction President and CEO of this company sold 140,182 shares at a rate of $3.85, taking the stock ownership to the 625,948 shares. Before that another transaction happened on Feb 13 ’25, when Company’s President and CEO sold 75,324 for $3.70, making the entire transaction worth $278,699. This insider now owns 883,089 shares in total.
Relay Therapeutics Inc (RLAY) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.51 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.41% during the next five years compared to -23.05% drop over the previous five years of trading.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
You can see what Relay Therapeutics Inc (RLAY) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 15.95. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 50.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.40, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -2.34 in one year’s time.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Looking closely at Relay Therapeutics Inc (NASDAQ: RLAY), its last 5-days average volume was 2.63 million, which is a jump from its year-to-date volume of 2.35 million. As of the previous 9 days, the stock’s Stochastic %D was 4.21%. Additionally, its Average True Range was 0.28.
During the past 100 days, Relay Therapeutics Inc’s (RLAY) raw stochastic average was set at 1.26%, which indicates a significant decrease from 4.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 75.43% in the past 14 days, which was lower than the 75.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.93, while its 200-day Moving Average is $5.82. However, in the short run, Relay Therapeutics Inc’s stock first resistance to watch stands at $3.06. Second resistance stands at $3.15. The third major resistance level sits at $3.22. If the price goes on to break the first support level at $2.89, it is likely to go to the next support level at $2.82. Should the price break the second support level, the third support level stands at $2.73.
Relay Therapeutics Inc (NASDAQ: RLAY) Key Stats
There are 169,522K outstanding shares of the company, which has a market capitalization of 501.79 million. As of now, sales total 10,010 K while income totals -337,710 K. Its latest quarter income was 0 K while its last quarter net income were -76,000 K.
